Leading CROs unifying trial data and processes for greater visibility and speed<\/em><\/p>\n BARCELONA, Spain – 17 Oct. 2022 \u2014<\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS<\/a> to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs. These global leaders \u2013 Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc., and Syneos Health \u2013 are unifying clinical on a single platform as they expand their use of Veeva Vault Clinical Suite<\/a> from Vault eTMF<\/a> to now include Vault CTMS. <\/p>\n Also selected by more than 120 sponsors, including 9 of the top 20 pharmaceutical companies, Vault CTMS has fast become the industry-leading solution for clinical trial management. As CROs increasingly standardize on Vault CTMS, they can support sponsor preference for Veeva Vault while modernizing study operations for more efficient execution. <\/p>\n Vault CTMS provides a complete view of trial metrics so CROs can better manage study performance and increase transparency to sponsors. Sponsors and CROs using Vault CTMS work on a consistent industry standard platform that makes it easier to collaborate and share study information for real-time visibility across the study portfolio. <\/p>\n \u201cVeeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs,\u201d said Henry Galio, vice president, Veeva Vault CTMS. \u201cAs more companies advance trial operations with Veeva, sponsors, CROs, and sites can work closer together to drive faster study endpoints and accelerate subject enrollment in trials.\u201d <\/p>\n Vault CTMS is part of the Veeva Vault Clinical Operations Suite<\/a>, enabling companies to share information and documents across eTMF, CTMS, payments, study start-up, and study training for better collaboration and execution throughout the study lifecycle. <\/p>\n Additional Information<\/strong><\/br> About Veeva Systems<\/strong> Veeva Forward-looking Statements<\/strong> ###<\/p>\n Contact:<\/strong><\/p>\n Jeremy Whittaker
\nFor more on Veeva Vault CTMS, visit: veeva.com\/eu\/CTMS<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a>
\n<\/p>\n
\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n
\nVeeva Systems
\n+49 6950955486
\njeremy.whittaker@veeva.com<\/a><\/p>\n